Eptifibatide
Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Eptifibatide0.83 kDa
Mechanistic Evidence Box
Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.- Page type
- Compound profile
- Evidence type
- Clinical and regulatory evidence (FDA-approved derived drug)
- Evidence level
- FDA-cleared regulatory context
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
Eptifibatide is a synthetic cyclic heptapeptide designed from the KGD sequence of the snake-venom disintegrin barbourin (Scarborough 1991, 1993); it is not derived from leech decorsin. Its RCT evidence base (PURSUIT) applies only to the drug, not to whole medicinal-leech therapy.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Tier A — FDA-approved derivative
- Molecular weight
- 831.96 Da
- Source species
- Synthetic peptidomimetic
- Discovered
- 1993 · COR Therapeutics (designed from the KGD sequence of barbourin, a disintegrin from the venom of Sistrurus miliarius barbouri)
- PubChem CID
- 123610
- Derived FDA-approved drug
- Integrilin (FDA approved May 1998)
Biological Targets
- → platelet integrin αIIbβ3 (GP IIb/IIIa)
Key Citations
- Scarborough RM et al. (1991), J Biol Chem · PMID 2033037
- Scarborough RM et al. (1993), J Biol Chem · PMID 8419315
- PURSUIT Trial Investigators (1998), N Engl J Med · PMID 9705684
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.